动脉粥样硬化性心血管疾病患者血脂分布及不同剂量的阿托伐他汀降脂达标情况分析  

Lipid profiles in patients with arteriosclerotic cardiovascular disease and control rate of different doses of atorvastatin on lowering low-density lipoprotein cholesterol concentration

作　　者：胡彦[1] 桑学东[1] 

机构地区：[1]福建医科大学附属漳州市医院,福建漳州363000

出　　处：《岭南心血管病杂志》2016年第4期412-414,423,共4页South China Journal of Cardiovascular Diseases

摘　　要：目的分析漳州地区动脉粥样硬化性心血管疾病(arteriosclerotic cardiovascular disease,ASCVD)患者的血脂分布及他汀类药物应用情况,探讨不同剂量的阿托伐他汀对ASCVD患者的降脂达标效果。方法选择到漳州市医院就诊的ASCVD患者356例,检测其血脂[三酸甘油(triacylglyceml,TG),总胆固醇(total cholesterol,TC),低密度脂蛋白胆固醇(low-density lipoprotein cholesterol,LDL-C),高密度脂蛋白胆固醇(high-density lipoprotein cholesterol,HDL-C)]浓度分析血脂分布及他汀类药物应用情况。按随机数字表法分为小剂量阿托伐他汀组(n=179,10 mg睡前顿服一次)及常规剂量阿托伐他汀组(n=187,20 mg睡前顿服一次),疗程均为3个月。检测两组患者治疗后血脂浓度,同时对两组患者的血糖、肝功能、肾功能、肌酸激酶进行检测。结果漳州地区ASCVD患者治疗前TG为(1.66±0.95)mmol/L,TC为(5.76±0.68)mmol/L,LDL-C为(3.52±0.54)mmol/L,HDL-C为(1.23±0.42)mmol/L。治疗3个月后,两组患者的血清TG、TC、LDL-C浓度均比治疗前显著降低,差异有统计学意义(P<0.01)。以LDL-C 1.8 mmol/L为降脂目标值,小剂量阿托伐他汀组降幅36%,常规剂量阿托伐他汀组降幅为42.3%,两组达标率为38%和53%。结论漳州地区ASCVD患者的血脂处于较高水平;小剂量及常规阿托伐他汀能够显著降低LDL-C浓度,但达标率仍处于较低水平。Objectives To investigate the lipid profiles in patients with arteriosclerotic cardiovascular disease （ASCVD） in Zhangzhou Region and the roles of different doses of atorvastatin in lowering low-density lipoprotein cholesterol （LDL-C） concentration. Methods Three hundred and fifty-six patients with ASCVD were included in this study. Serum concentrations of triglyceride （TG）, total cholesterol （TC）, LDL-C and high-density lipoprotein cholesterol （HDL-C） were measured to analyze the lipid profiles and statins utility. Then the patients were randomly divided into low-dose treatment group （n= 179） and standard-dose treatment group （n= 187）. Low-dose treatment group was given atorvastatin 10 mg once daily at bedtime and standard-dose treatment group received atorvastatin 20 mg once daily at bedtime. The two groups were treated for 3 months. After treatment, lipid concentration, blood glucose, renal function, liver function and creatine kinase （CK） concentration of the two groups were measured. Results Serum concentrations of TG, TC, LDL-C and HDL-C were （1.66±0.95） mmol/L, （5.76±0.68） mmol/L, （3.52±0.54） mmol/L and （1.23± 0.42） mmol/L in patients with ASCVD before treatment. After treatments with low-dose and standard-dose of atorvastatin for 3 months, serum concentrations of TG, TC and LDL-C significantly reduced （all P〈0.01 ）. Taking LDL-C 1.8 mmol/L as the target value, decreasing amplitude in low-dose treatment group was 36%, in standard-dose treatment group was 42.3%. Control rates in low-dose treatment group and standard-dose treatment group were 38% and 53%, respectively. Conclusions The lipid profiles of ASCVD patients in Zhangzhou Region are high. Both low-dosage and standard-dosage of atorvastatin treatment can significantly lower LDL-C concentration, but with a low control rate.

关 键 词：动脉硬化性心血管疾病 阿托伐他汀 低密度脂蛋白胆固醇 达标 

分 类 号：R543.5[医药卫生—心血管疾病]